Key Findings
Porton Advanced is significantly bolstering its end-to-end Contract Development and Manufacturing Organization (CDMO) solutions for Advanced Therapy Medicinal Products (ATMPs), catering to a robust client base of over 250 global customers. The company offers a comprehensive suite of services encompassing cell engineering CMC (Chemistry, Manufacturing, and Controls) for both autologous and allogeneic cells, as well as production of plasmids, lentiviruses, mRNA and Lipid Nanoparticles (LNPs), and bacterial vectors.
Technical / Clinical Details
Porton Advanced’s strengthened ATMP CDMO services are characterized by the following extensive capabilities:
- Cell Engineering CMC Services: Provides full CMC support for both autologous cell therapies (modifying a patient’s own cells) and the more scalable allogeneic cell therapies (using universal donor cells). This ensures quality and efficacy of cell therapy products and facilitates regulatory approval processes.
- Diverse Gene Delivery Vector Offerings: The company supports a wide array of gene delivery technologies, including plasmid DNA, viral vectors such as lentiviruses and adeno-associated viruses (AAVs), as well as mRNA encapsulated in LNPs, and bacterial vectors. This flexibility allows clients to choose the optimal vector system tailored to their specific therapeutic goals and safety requirements.
- Extensive Track Record and Experience: With a record of assisting over 24 Investigational New Drug (IND) clearances and manufacturing more than 400 GMP (Good Manufacturing Practice) compliant batches, Porton Advanced demonstrates deep technical expertise and strong regulatory acumen, offering reliable partnerships to clients.
- Integrated CRO/CDMO Capabilities: By providing seamless support from the research stage (CRO) through development and manufacturing (CDMO), the company mitigates technology transfer risks, accelerates development timelines, and promotes efficient commercialization.
Background & Context
The ATMP sector, driven by innovative approaches in gene therapy, cell therapy, and tissue engineering, is rapidly expanding, offering new treatment options for intractable diseases. However, manufacturing these therapies is exceptionally complex, requiring specialized expertise, stringent quality control, and substantial capital investment in facilities. Consequently, many pharmaceutical and biotechnology companies opt to outsource their manufacturing processes to specialized CDMOs. Companies like Porton Advanced are critical in meeting this rising demand and accelerating the market entry of ATMPs.
Strategic Significance & Outlook
The enhancement of Porton Advanced’s end-to-end CDMO solutions is expected to further accelerate the development and commercialization of ATMPs. With capabilities across diverse modalities and a solid track record, the company is solidifying its position as a key global partner in the cell and gene therapy space. This will lead to more groundbreaking therapies being delivered to patients rapidly and efficiently, making an indispensable contribution to addressing global healthcare needs and shaping the future of disease treatment.
Source: https://www.portonadvanced.com/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments